Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Rhythm Pharmaceuticals Inc (RYTM)

Rhythm Pharmaceuticals Inc (RYTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 736,845
  • Shares Outstanding, K 34,432
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,060 K
  • 60-Month Beta 1.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.80
  • Number of Estimates 3
  • High Estimate -0.72
  • Low Estimate -0.93
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -53.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.64 +3.83%
on 06/25/19
26.24 -18.33%
on 05/28/19
-4.57 (-17.58%)
since 05/24/19
3-Month
20.64 +3.83%
on 06/25/19
31.84 -32.69%
on 03/27/19
-10.23 (-32.31%)
since 03/26/19
52-Week
20.64 +3.83%
on 06/25/19
37.23 -42.44%
on 06/27/18
-13.77 (-39.12%)
since 06/26/18

Most Recent Stories

More News
Rhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

RYTM : 21.75 (+1.64%)
Recent Analysis Shows Fortinet, Dunkin' Brands Group, 8x8, Rhythm Pharmaceuticals, Antero Resources, and Casella Waste Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Fortinet, Inc. (NASDAQ:FTNT),...

AR : 5.52 (+2.22%)
FTNT : 75.39 (+0.69%)
RYTM : 21.75 (+1.64%)
CWST : 38.95 (-2.09%)
DNKN : 79.45 (-0.64%)
EGHT : 23.21 (-0.43%)
Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

RYTM : 21.75 (+1.64%)
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders

Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) ("Knight" or the "Company"), today announced...

PTCT : 41.79 (-0.55%)
KERX : 3.36 (-2.04%)
GUD.TO : 7.71 (-0.13%)
RYTM : 21.75 (+1.64%)
AKBA : 4.64 (+4.74%)
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today reported...

RYTM : 21.75 (+1.64%)
Rhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced...

RYTM : 21.75 (+1.64%)
Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Alexion Pharmaceuticals,...

AFI : 9.84 (-0.51%)
RYAM : 6.23 (+2.30%)
RYTM : 21.75 (+1.64%)
PLUG : 2.19 (+6.83%)
ALXN : 123.92 (-0.98%)
SXC : 8.58 (+2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade RYTM with:

Business Summary

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide,...

See More

Key Turning Points

2nd Resistance Point 22.64
1st Resistance Point 22.02
Last Price 21.75
1st Support Level 20.71
2nd Support Level 20.02

See More

52-Week High 37.23
Fibonacci 61.8% 30.89
Fibonacci 50% 28.93
Fibonacci 38.2% 26.98
Last Price 21.75
52-Week Low 20.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar